Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 20/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6906219 | 0.77 | ADORA2A (0.56) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL6903430 | 0.75 | ADORA2A (0.55) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL6899152 | 0.73 | ADORA2A (0.73) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL6906303 | 0.71 | ADORA2A (0.55) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL2988512 | 0.71 | ADORA2A (0.71) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL4046641 | 0.70 | ADORA2A (0.66) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL2992358 | 0.70 | ADORA2A (0.74) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL2995678 | 0.69 | ADORA2A (0.57) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL4044812 | 0.68 | ADORA2A (0.81) | ADORA2AADORA3ADORA2BADORA1 | |
| SCHEMBL2988037 | 0.68 | ADORA2A (0.56) | ADORA2AADORA3ADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040097526-A1 | Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists | VERNALIS DEVELOPMENT LIMITED (GB) | 2004-05-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097526-A1 | Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists | CHRNA5, CHRNA4, CNR1 | ADORA2A 7/4885ADORA3 17/4885ADORA2B 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.